Good
Mostly Aligned
Patient Risk:
Low
Summary
All four statements are consistent with the supplied label excerpts regarding active ingredients and fixed-dose combination use; however, label text provided does not explicitly use the terms “generic name” or “marketed as” for labeling-form wording, so minor terminology alignment cannot be fully confirmed.
Category Scores
Accurate Statements
Bevespi’s generic name is glycopyrrolate/formoterol.
The label identifies active ingredients as glycopyrrolate and formoterol fumarate (Sections 3 and 2.1/Drug description context provided).
Bevespi Aerosphere is marketed as a fixed-dose combination of glycopyrronium and formoterol.
The label describes BEVESPI AEROSPHERE delivering both glycopyrrolate and formoterol fumarate per inhalation and dosing both together (Sections 3 and 2.1).
Bevespi is a combination inhaler.
Both active ingredients are included in the inhalation aerosol and administered together (Sections 3 and 2.1).
Bevespi’s generic naming reflects both active ingredients rather than one compound name.
The label specifies two active ingredients (glycopyrrolate and formoterol fumarate) in the product composition (Sections 3 and 2.1).
Unsupported Statements
Bevespi’s generic name is glycopyrrolate/formoterol.
The supplied label excerpts confirm the active ingredients but do not explicitly use the phrase “generic name” or the exact generic naming format “glycopyrrolate/formoterol.”
Bevespi Aerosphere is marketed as a fixed-dose combination of glycopyrronium and formoterol.
The excerpts support fixed-dose co-delivery via labeled strengths but do not explicitly state the marketing phrasing “marketed as” or the term “fixed-dose combination.”
Bevespi’s generic naming reflects both active ingredients rather than one compound name.
The label excerpts establish two active ingredients, but do not explicitly discuss how generic naming is constructed (e.g., whether it is described as a generic “name” vs. active ingredient listing).
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The statements are descriptive about active ingredients and combination composition; the supplied label excerpts do not indicate risks arising from misidentifying the active ingredient names alone.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Terminology precision: the excerpts confirm active ingredients and co-formulation, but do not explicitly provide the exact phrasing “generic name” or “marketed as a fixed-dose combination.”
Suggested Improvement
Rephrase to match label language, e.g., “BEVESPI AEROSPHERE contains glycopyrrolate and formoterol fumarate (two active ingredients) in a pressurized metered-dose inhaler; each inhalation delivers specified microgram amounts.”